Data on gencaro impact on prevention of bradycardia published in heart rhythm o2

Westminster, colo., jan. 04, 2022 (globe newswire) -- arca biopharma, inc. (nasdaq: abio), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the paper entitled “dose limiting, adverse event associated bradycardia with Β-blocker treatment of atrial fibrillation in the genetic-af trial” (william abraham, et al) has been published in heart rhythm o 2 , a publication of the hearth rhythm society. the paper details an analysis that examined the prevalence of bradycardia and its association with adverse events (aes) and failure to achieve target dose in the genetic-af phase 2b clinical trial. in the genetically defined population of genetic-af (all adrb1 arg389arg genotype), the prevalence of clinically important bradycardia was lower for gencaro compared to metoprolol, with an incidence of heart rate (hr)
ABIO Ratings Summary
ABIO Quant Ranking